Data obtained from in vivo testing of catalytic cleft specific small molecule drugs may better reveal the relative importance of the enzymatic function of heparanase, compared to its non-enzymatic activities, in tumor progression, than was the case with the anti-heparanase drugs that have currently entered clinical trial. The gene discussed is HPSE; the disease is neoplasm.